FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106121462> ?p ?o ?g. }

• W3106121462 abstract "Background Avelumab, a human anti–PD-L1 monoclonal antibody, has shown a manageable safety profile and antitumor activity in multiple tumor types, including platinum-resistant metastatic or recurrent NSCLC, 1 and is approved for patients with locally advanced or metastatic UC who have progressed after ≥1 previous line of platinum-based chemotherapy 2 3 and as maintenance treatment for those who have not progressed with platinum-based chemotherapy. 4 JAVELIN Medley VEGF ( NCT03472560 ) evaluated the efficacy and safety of avelumab + axitinib, a potent inhibitor of VEGFR 1, 2, and 3, in patients with advanced or metastatic NSCLC or UC. Methods Eligible patients with NSCLC had received ≥1 prior platinum-containing therapy and ≤2 prior lines of systemic therapy for locally advanced or metastatic disease; patients with UC were treatment naive in the locally advanced or metastatic setting and ineligible for cisplatin-containing chemotherapy. Patients were immune checkpoint inhibitor naïve and received avelumab 800 mg intravenously every 2 weeks + axitinib 5 mg orally twice daily. The primary endpoint was confirmed objective response (OR) per investigator assessment (RECIST 1.1). Secondary endpoints included progression-free survival (PFS) and safety. PD-L1 expression was assessed in baseline tumor samples (Ventana SP263 assay). Data have not undergone standard quality checks and are subject to change due to COVID-19–related healthcare burden. Results A total of 41 patients with NSCLC and 20 with UC received avelumab + axitinib. The confirmed OR rate was 31.7% (95% CI, 18.1–48.1) in the NSCLC cohort and 10% (95% CI, 1.2–31.7) in the UC cohort (all partial responses); 16 patients (39.0%) and 5 (25.0%) had stable disease, respectively. Responses were observed regardless of PD-L1 expression status. Median PFS was 5.5 months (95% CI, 2.5–7.0) in the NSCLC cohort and 2.3 months (95% CI, 1.8–5.6) in the UC cohort. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 24 patients (58.5%) in the NSCLC cohort; the most common was hypertension (n=7 [17.1%]). Grade ≥3 TRAEs occurred in 9 patients (45.0%) in the UC cohort; the most common were amylase increased, asthenia, decreased appetite, and palmar-plantar erythrodysesthesia syndrome (n=2 [10%] each). One patient in each cohort experienced a TRAE that led to death (gastric perforation and urinary bladder hemorrhage). Conclusions Avelumab + axitinib showed antitumor activity and a manageable safety profile in patients with advanced or metastatic NSCLC or UC consistent with findings from studies of each drug alone and in combination. Trial Registration NCT03472560 Ethics Approval The study was approved by each site’s independent ethics committee. Consent N/A References Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 2017;18:599–610. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64. Bavencio(avelumab) injection. [package insert] Darmstadt, Germany: Merck KGaA; 2019. US Food and Drug Administration. FDA approves avelumab for urothelial carcinoma maintenance treatment. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed August 19, 2020." @default.
• W3106121462 created "2020-11-23" @default.
• W3106121462 creator A5002069056 @default.
• W3106121462 creator A5010114443 @default.
• W3106121462 creator A5016654748 @default.
• W3106121462 creator A5017555080 @default.
• W3106121462 creator A5023055777 @default.
• W3106121462 creator A5028823803 @default.
• W3106121462 creator A5031005721 @default.
• W3106121462 creator A5034739279 @default.
• W3106121462 creator A5035148529 @default.
• W3106121462 creator A5037677450 @default.
• W3106121462 creator A5037860810 @default.
• W3106121462 creator A5041689810 @default.
• W3106121462 creator A5044075250 @default.
• W3106121462 creator A5046409560 @default.
• W3106121462 creator A5053512779 @default.
• W3106121462 creator A5054564180 @default.
• W3106121462 creator A5064206524 @default.
• W3106121462 creator A5064697305 @default.
• W3106121462 creator A5066140302 @default.
• W3106121462 creator A5069675443 @default.
• W3106121462 creator A5070376639 @default.
• W3106121462 creator A5073284312 @default.
• W3106121462 date "2020-11-01" @default.
• W3106121462 modified "2023-09-27" @default.
• W3106121462 title "281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)" @default.
• W3106121462 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0281" @default.
• W3106121462 hasPublicationYear "2020" @default.
• W3106121462 type Work @default.
• W3106121462 sameAs 3106121462 @default.
• W3106121462 citedByCount "2" @default.
• W3106121462 countsByYear W31061214622021 @default.
• W3106121462 countsByYear W31061214622022 @default.
• W3106121462 crossrefType "proceedings-article" @default.
• W3106121462 hasAuthorship W3106121462A5002069056 @default.
• W3106121462 hasAuthorship W3106121462A5010114443 @default.
• W3106121462 hasAuthorship W3106121462A5016654748 @default.
• W3106121462 hasAuthorship W3106121462A5017555080 @default.
• W3106121462 hasAuthorship W3106121462A5023055777 @default.
• W3106121462 hasAuthorship W3106121462A5028823803 @default.
• W3106121462 hasAuthorship W3106121462A5031005721 @default.
• W3106121462 hasAuthorship W3106121462A5034739279 @default.
• W3106121462 hasAuthorship W3106121462A5035148529 @default.
• W3106121462 hasAuthorship W3106121462A5037677450 @default.
• W3106121462 hasAuthorship W3106121462A5037860810 @default.
• W3106121462 hasAuthorship W3106121462A5041689810 @default.
• W3106121462 hasAuthorship W3106121462A5044075250 @default.
• W3106121462 hasAuthorship W3106121462A5046409560 @default.
• W3106121462 hasAuthorship W3106121462A5053512779 @default.
• W3106121462 hasAuthorship W3106121462A5054564180 @default.
• W3106121462 hasAuthorship W3106121462A5064206524 @default.
• W3106121462 hasAuthorship W3106121462A5064697305 @default.
• W3106121462 hasAuthorship W3106121462A5066140302 @default.
• W3106121462 hasAuthorship W3106121462A5069675443 @default.
• W3106121462 hasAuthorship W3106121462A5070376639 @default.
• W3106121462 hasAuthorship W3106121462A5073284312 @default.
• W3106121462 hasConcept C121608353 @default.
• W3106121462 hasConcept C126322002 @default.
• W3106121462 hasConcept C143998085 @default.
• W3106121462 hasConcept C203092338 @default.
• W3106121462 hasConcept C2776256026 @default.
• W3106121462 hasConcept C2776539811 @default.
• W3106121462 hasConcept C2776694085 @default.
• W3106121462 hasConcept C2777381376 @default.
• W3106121462 hasConcept C2777701055 @default.
• W3106121462 hasConcept C2778239845 @default.
• W3106121462 hasConcept C2778822529 @default.
• W3106121462 hasConcept C2779490328 @default.
• W3106121462 hasConcept C2779984678 @default.
• W3106121462 hasConcept C2780030458 @default.
• W3106121462 hasConcept C2780352672 @default.
• W3106121462 hasConcept C2911057145 @default.
• W3106121462 hasConcept C3019882237 @default.
• W3106121462 hasConcept C535046627 @default.
• W3106121462 hasConcept C71924100 @default.
• W3106121462 hasConceptScore W3106121462C121608353 @default.
• W3106121462 hasConceptScore W3106121462C126322002 @default.
• W3106121462 hasConceptScore W3106121462C143998085 @default.
• W3106121462 hasConceptScore W3106121462C203092338 @default.
• W3106121462 hasConceptScore W3106121462C2776256026 @default.
• W3106121462 hasConceptScore W3106121462C2776539811 @default.
• W3106121462 hasConceptScore W3106121462C2776694085 @default.
• W3106121462 hasConceptScore W3106121462C2777381376 @default.
• W3106121462 hasConceptScore W3106121462C2777701055 @default.
• W3106121462 hasConceptScore W3106121462C2778239845 @default.
• W3106121462 hasConceptScore W3106121462C2778822529 @default.
• W3106121462 hasConceptScore W3106121462C2779490328 @default.
• W3106121462 hasConceptScore W3106121462C2779984678 @default.
• W3106121462 hasConceptScore W3106121462C2780030458 @default.
• W3106121462 hasConceptScore W3106121462C2780352672 @default.
• W3106121462 hasConceptScore W3106121462C2911057145 @default.
• W3106121462 hasConceptScore W3106121462C3019882237 @default.
• W3106121462 hasConceptScore W3106121462C535046627 @default.
• W3106121462 hasConceptScore W3106121462C71924100 @default.
• W3106121462 hasLocation W31061214621 @default.
• W3106121462 hasOpenAccess W3106121462 @default.
• W3106121462 hasPrimaryLocation W31061214621 @default.
• W3106121462 hasRelatedWork W2144331923 @default.
• W3106121462 hasRelatedWork W2217070258 @default.

• next